Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.41 +0.02 (+0.34%)
At close: Aug 20, 2026 · 10:51 AM UTC

Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Operating Income came in at -$7.0 million in Q4 2025, down 2454.32% YoY from $299026.3 in Q4 2024, and down 281.73% on a QoQ basis from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Operating Income data on file, last reported at -$7.0 million in Q4 2025.

  • Quarterly Operating Income fell 2454.32% year-over-year to -$7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.9 million (down 834.25% YoY) and the FY2025 annual result came in at -$11.9 million, down 834.25% from the prior year.
  • Operating Income fell to -$7.0 million in Q4 2025, from -$1.8 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$271726.0 in Q1 2024 to a low of -$7.0 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Haleon 43.65 Bn 42.68 Bn - -
2 Teva Pharmaceutical Industries 43.09 Bn 39.44 Bn 2.15 Bn -231.00 Mn
3 Zoetis 31.54 Bn 29.86 Bn 1.05 Bn 837.00 Mn
4 Takeda Pharmaceutical 28.61 Bn 22.81 Bn 5.10 Bn 1.26 Bn
5 United Therapeutics 22.11 Bn 19.45 Bn 683.80 Mn 330.80 Mn
6 Viatris 18.77 Bn 17.88 Bn 1.46 Bn 6.30 Mn
7 Neurocrine Biosciences 15.62 Bn 15.23 Bn 935.80 Mn 151.50 Mn
8 Elanco Animal Health 12.07 Bn 11.54 Bn 798.00 Mn 248.00 Mn
9 Dr Reddys Laboratories 10.09 Bn 9.93 Bn - -
10 Apimeds Pharmaceuticals US 7.52 Mn 7.52 Mn - -6.28 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.04 Mn
Sep 30, 2025 -1.84 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -364,368.00
Dec 31, 2024 -275,613.00
Sep 30, 2024 -299,999.00
Jun 30, 2024 -427,757.00
Mar 31, 2024 -271,726.00